The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TAP, STMP and AMRN

Klein 律师事务所提醒投资者注意 TAP 、 STMP 和 AMRN 股东的集体诉讼

2019-04-05 02:30:00 ACCESSWIRE


NEW YORK, NY / ACCESSWIRE / April 4, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. Molson Coors Brewing Company (TAP)Class Period: February 14, 2017 to February 12, 2019Lead Plaintiff Deadline: April 16, 2019 During the class period, Molson Coors Brewing Company allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Molson Coors failed to properly reconcile the outside basis deferred income tax liability for Molson Coors' investment in its MillerCoors, LLC partnership; (2) consequently, Molson Coors misreported net income in its consolidated financial statements for the fiscal years ending December 31, 2016 and December 31, 2017, resulting in an overall downward revision to net income; (3) Molson Coors lacked adequate internal controls over financial reporting; and (4) as a result, defendants' statements about Molson Coors' business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Get additional information about the TAP lawsuit: Inc. (STMP)Class Period: May 3, 2017 to February 21, 2019Lead Plaintiff Deadline: April 29, 2019 The complaint alleges that during the class period Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's financial results depended on the manipulation of a USPS program that cost USPS an estimated $235 million per year; and (ii) as a result, the Company's business was unsustainable and its financial results were highly misleading. Get additional information about the STMP lawsuit: Amarin Corporation (AMRN)Class Period: September 24, 2018 to November 9, 2018Lead Plaintiff Deadline: April 23, 2019 The lawsuit alleges that Amarin Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin's public statements were materially false and misleading at all relevant times. Get additional information about the AMRN lawsuit: Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided. J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: J. Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 SOURCE: The Klein Law Firm
纽约,纽约/ ACCESSWIRE /2019年4月4日/ Klein 律师事务所宣布,已代表下列公司的股东提出集体诉讼申诉。如果你蒙受了损失,你必须在主原告最后期限之前请求法院指定你为主原告。 Molson Cooks Brewing Company ( TAP ) Class Period :2017年2月14日至2012年2月12日主要原告截止日:2019年4月16日 于课期间, Molson Coors Brewing Company 涉嫌作出重大虚假及╱或具误导性陈述及╱或未能披露:(1) Molson Coors 未能就 Molson Coors 于其 MillerCoors , LLC 合伙企业之投资作出适当调整外基准递延所得税负债;(2)因此,Molson Cooks 在其截至2016年12月31日和2017年12月31日的财政年度的合并财务报表中错误报告了净利润,导致对净利润的总体向下修正;(3) Molson Cooks 对财务报告缺乏充分的内部控制;(4)因此,被告关于 Molson Cooks 的业务、运营和前景的报表在所有相关时间都存在重大错误和误导,和/或缺乏合理的基础。 获取有关 TAP 诉讼的更多信息: ?电线=3 邮票.com Inc .( STMP )类期限:2017年5月3日至2012年2月21日主要原告期限:2019年4月29日 控罪指在上课期间盖章。com Inc .作出重大虚假及/或误导性陈述,及/或未能披露:( i )本公司的财务业绩取决于美国邮政计划的操纵,该计划估计每年导致美国邮政公司损失2.35亿美元;( ii )因此,本公司的业务不可持续,其财务业绩极具误导性。 获取有关 STMP 诉讼的更多信息: ?电线=3 Amarin Corporation ( AMRN )类期限:2018年9月24日至2011年11月9日主要原告期限:2019年4月23日 该诉讼声称, Amarin 公司作出了实质性的虚假和/或误导性陈述和/或未能披露:(1) Amarin 吹嘘其对 Vasicpa 的 REDUCE-IT 试验的顶级结果不如公司所代表的积极;(2)给予 REDUCE-IT 控制部门患者的安慰剂可能增加了这些患者心血管事件的发生率;(3)因此,Amarin 的公开声明在任何相关时间都是实质性的虚假和误导。 获取关于 AMRN 诉讼的更多信息: ?电线=3 你分享任何赔偿的能力并不要求你作为主要原告。你没有任何费用或义务。如果您在上课期间遭受了损失,并希望获得更多信息,请联系 J.Klein , Esq 。致电212-616-4899或浏览网页。 J 。Klein , Esq 。代表投资者参与全国范围内涉及金融欺诈的证券诉讼。律师广告。先前的结果并不能保证类似的结果。 合同内容: J 。Klein , Esq 。 帝国大厦 第五大道350号 59楼 纽约,纽约10118 jk @ 电话:(212)616-4899 传真:(347)558-9665 SOURCE : Klein 律师事务所